Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.
Marc A RiedlE Aygören-PürsünJ BakerHenriette FarkasJ AndersonJonathan A BernsteinLaurence BouilletP BusseM ManningM MagerlM GompelsA P HuissoonH LonghurstW LumryB RitchieR ShapiroD SoteresA BanerjiM CancianD T JohnstonT J CraigD LaunayH H LiM LiebhaberT NickelJ OffenbergerW RaeR SchrijversM TriggianiH J WednerS DoboM CornpropstD ClemonsL FangP CollisWilliam P SheridanMarcus MaurerPublished in: Allergy (2018)
Although this study did not demonstrate efficacy of avoralstat in preventing angioedema attacks in C1-INH-HAE, it provided evidence of shortened angioedema episodes and improved QoL in the avoralstat 500 mg treatment group compared with placebo.